We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
To produce components needed for their COVID-19 vaccine candidates, Novavax has enlisted support from a South Korean biotech, while Johnson & Johnson has agreed to work with an Indian biopharma company. Read More
AstraZeneca has entered into an agreement with mAbxience of the INSUD Group to produce AZ’s COVID-19 vaccine for most of Latin America from manufacturing facilities in Mexico and Argentina. Read More
Health insurer Humana has filed a lawsuit against Teva Pharmaceuticals seeking to recover “substantial costs” it incurred in recalling and replacing the company’s heartburn drugs. Read More
Moderna has secured a $1.5 billion Operation Warp Speed contract to supply 100 million doses of a COVID-19 vaccine candidate to the U.S. government, with an option to supply 400 million more doses if needed. Read More
Novavax plans to have enough COVID-19 vaccine manufacturing capacity to meet U.S. demand at a minimum, but the Maryland-based vaccine developer is also looking to be able to supply billions of doses next year, the company’s CEO said. Read More
Moderna said that it might not be the first company to make the inventions claimed on patent applications for its COVID-19 vaccine mRNA-1273, and that the company may have to seek patent licenses to market the vaccine. Read More